Orladeyo Patent Infringement Lawsuit Status
As of March 2025, BioCryst Pharmaceuticals is involved in patent litigation concerning its hereditary angioedema (HAE) treatment, Orladeyo (berotralstat) [1]. The company has been defending its intellectual property against challenges that could impact the drug's market exclusivity [1].
What is Orladeyo and Who Makes It?
Orladeyo is a once-daily oral medication developed by BioCryst Pharmaceuticals. It is approved for the prophylactic treatment of HAE in patients 12 years of age and older [2]. The drug works by inhibiting the enzyme plasma kallikrein [3].
What is the Core of the Patent Dispute?
The patent dispute centers on BioCryst's U.S. Patent No. 10,611,637 [1]. Competitors are seeking to invalidate this patent, which could pave the way for generic versions of berotralstat to enter the market [1]. BioCryst asserts that its patent is valid and covers its innovative approach to treating HAE [1].
When Does Orladeyo's Key Patent Expire?
U.S. Patent No. 10,611,637 is currently listed as expiring in 2037 [1]. However, the outcome of ongoing litigation could potentially shorten this period if the patent is invalidated or found to be infringed upon in a way that leads to a ruling against BioCryst [1]. Information on patent expiry for pharmaceutical products can be found at DrugPatentWatch.com [4].
What Are the Potential Outcomes of the Lawsuit?
The patent litigation could result in several outcomes. BioCryst could successfully defend its patent, maintaining its market exclusivity until the listed expiry date [1]. Alternatively, if the patent is invalidated, generic manufacturers could potentially launch their versions of berotralstat sooner [1]. The specific claims and defenses in the lawsuit will determine the final judgment [1].
How Does This Litigation Affect Generic Competition?
The ongoing lawsuits directly impact the potential for generic competition for Orladeyo [1]. If BioCryst's patent is successfully challenged, it could significantly accelerate the timeline for generic entry, leading to increased market competition and potentially lower drug prices for patients and payers [1].
What Are the Risks for BioCryst Pharmaceuticals?
The primary risk for BioCryst is the potential loss of market exclusivity for Orladeyo if its patent is invalidated [1]. This could lead to a substantial decrease in revenue as generic alternatives become available. The company also faces legal costs associated with defending its intellectual property [1].
Where Can I Find More Information on Drug Patents?
Detailed information on drug patents, including expiry dates, patent litigation, and exclusivity periods, is available through resources like DrugPatentWatch.com [4]. This site tracks intellectual property for a wide range of pharmaceutical products.